300+ senior healthcare leaders navigating the rapidly evolving market and patient access landscape
By the Numbers
20+
sessions
70+
expert presentations
12
dedicated networking hours
1:1
curated meetings
WHY ACCESS FORUM? WHY NOW?
300+ senior healthcare leaders will descend on New Orleans to navigate the rapidly evolving market and patient access landscape in a completely reimagined Forum experience. You will explore how the new Administration in the US is driving unprecedented policy changes and global market dynamics creating worldwide ripple effects. Mastering both local and global strategy with cross-regional execution is now essential for success. The maelstrom demands expertise—and solutions. Patient access decisions made locally now reverberate globally, while evidence generation must resonate across continents and complex health structures.
SESSION TRACKS:
The U.S. market is experiencing significant shifts in policy, pricing, and distribution models that will define the future of access. This track invites proposals addressing topics such as:
The impact of U.S. healthcare policy changes, including IRA, IPAY, MFN, and executive orders
340B reform and its implications for stakeholders across the system
Evolving distribution models such as direct-to-consumer approaches
The role and challenges of PBMs in shaping access and pricing
Other U.S.-specific policy, payer, and market innovations affecting access strategies
Outside the U.S., market access landscapes are being redefined through regional collaborations, national policies, and country-specific innovations. This Track invites proposals exploring such topics as:
Pan-European initiatives such as EuHTANet and Joint Clinical Assessment (JCA)
Market-specific strategies and challenges in Europe, APAC, and Latin America
Policy frameworks that influence access and reimbursement outside the U.S.
Demonstrating and communicating value is central to market access. This track focuses on how real-world evidence and innovative methodologies can substantiate product value and strengthen payer and stakeholder engagement. Sessions may cover topics such as:
Success stories of RWE in supporting product adoption and reimbursement
Approaches for capturing and communicating RWE effectively in product value stories
Integrating evidence strategies across the lifecycle to drive access outcomes
Opportunities for global collaboration and alignment in value assessment and evidence generation
Digital transformation is reshaping every aspect of healthcare access, from how evidence is generated to how patients engage with care. This track focuses on the role of digital health, AI, and new technologies in accelerating access, creating efficiencies, and demonstrating value. Sessions may cover such topics such as:
Using AI to drive payer engagement and smarter decision-making
Digital tools and AI innovations that enhance patient experience and engagement
Case studies of innovative technologies immproving access and outcomes
Opportunities and challenges in capturing the value of digital solutions
ACCESS Forum US is more than just an event; it’s a curated experience that embraces quality over quantity.
INTEGRATED NETWORKING Forget the typical exhibit floor — we’ve reinvented the experience with vibrant lounges, leadership roundtables, and New Orleans–style cultural moments that spark real dialogue and guaranteed 1:1 connections. Attendance at ACCESS Forum US is intentionally limited to 400 leaders to ensure every conversation counts and every connection drives impact.
ATTENDANCE PATHWAYS
Invitation Only
Hosted Leaders
Traditional Registration
Limited Paid Passes
AGENDA
EVENT SCHEDULE
PRE-CONFERENCE
09:00–18:00
Executive Training Program: What you need to know to prepare for & oversee your Joint Clinical Assessment (JCA) Activities
19:00–21:00
Networking Event & Reception
Step into the vibrant heart of the Forum as the Networking Hall transforms into a lively social experience – complete with curated live talent, immersive activations, and strolling entertainers. Enjoy cocktails and conversation wiht peers and solution partners in an atmosphere designed for meaningful connections and spontaneous moments of inspiration.
CONFERENCE DAY 1
08:00 – 09:00
Breakfast, 1:1 Meetings & Network Lounges
09:00 – 09:15
Welcome Remarks
09:15–10:00
Keynote Presentation
TBA
10:00 – 11:00
Plenary 1
TBA
11:00 – 11:45
Parallel Sessions: Choose 1 of 4 Interactive Panels and Workshops
TBA
WS 1: WS 2: WS 3: WS 4:
13:00 – 14:30
Lunch, 1:1 Meetings & Networking Lounges
14:30 – 15:45
Parallel Sessions: Choose 1 of 4 Interactive Panels & Workshops
Mardi Gras Nights! Second Line Parade & Offsite Reception
Join the rhythm of New Orleans as our very own ACCESS Forum marching band leads attendees from the Roosevelt down iconic Bourbon Street – accompanied by lively street performers – culminating in an unforgettable offsite cocktail reception featuring gourment food stations and live music that captures the true spirit of the city.
Conference Day 2
07:00 – 08:00
Breakfast, 1:1 Meetings & Networking Lounges
08:00 – 08:15
Welcome Remarks
08:15 – 09:15
Keynote Presentation 2
TBA
09:15 – 10:00
Morning Break, 1:1 Meetings & Newtorking Lounges
10:00 – 11:15
Parallel Sessions: Choose 1 of 4 Interactive Panels and Workshops
WS 9: WS 10: WS 11: WS 12:
11:15 – 12:15
Lunch, 1:1 Meetings & Networking Lounges
12:15 – 13:30
Parallel Sessions: Choose 1 of 4 Interactive Panels & Workshops
WS 13: WS 14: WS 15: WS 16:
13:30 – 14:15
Afternoon Break, 1:1 Meetings & Network Lounges3
14:15 – 15:15
Plenary 3
TBA
15:15 – 15:30
Conclusion & Adjournment
PLANNING COMMITTEE
Rob Glik
VP & GM, Global Market Access Consulting, IQVA
Chair, Planning Committee
Joseph Boswell
President, ACCESS Forum
Yash Jalundhwala
Senior Director, Global Market Access & Pricing, Moderna
Antti Kourula
VP, Head of Global Market Access, CSL Behring
Betsy Lahue
Founder & CEO Alkemi
Annette Powers
SVP, Head Global Value Access & Public Policy Astellas
Michael Scholler
Head of Global Access, Value and Policy — New Product Planning Astellas
Amir Tahami
Head, Global Value, Access & Evidence Eisai
Sean Tunis
Principal Rubik's Health
Paul Villa
Disease Area Head, Respiratory, Global Pricing and Market Access GSK
Gergana Zlateva
VP, Global Access Strategy & Pricing, Oncology Global Access & Value Pfizer
JUST ANNOUNCED!
Don't miss these just-confirmed sessions at ACCESS Forum US '26! Additional sessions, speakers & timing will be announced November 11.
Successful Use Cases of Generative AI in Market Access: From Hype to Real-World Impact
Digital Health & AI This session highlights proven applications of generative AI across leading pharmaceutical organizations—spanning evidence synthesis, payer communication, HTA submissions, and access strategy optimization. Speakers will share practical lessons, governance approaches, and best practices demonstrating how AI enhances efficiency, transparency, and decision-making across the product lifecycle.
Illuminating the Patient Journey Between Clinical Visits
Evidence & Value This workshop examines how real-world connectivity data, wearables, and behavioral insights reveal the patient experience between clinical visits. Cross-stakeholder experts will discuss how these continuous data sources enhance understanding of adherence, outcomes, and quality of life—creating measurable value for manufacturers, payers, clinicians, and patients alike.
Free-Loading vs Free-Riding Under Most-Favored Nation Pricing: What Are Options for Countries to Carry Their Weight?
Global & Regional Market Access (ex-U.S.) This session explores global inequities in financing pharmaceutical innovation, examining how differential country contributions, pricing policies, and access delays affect R&D sustainability. Panelists will share findings from PhRMA and leading consultancies and discuss policy options to balance fairness, access, and shared responsibility across nations.
Global Market Access is Flux: How Regional Trends are Shaping Each Other
Global & Regional Market Access (ex-U.S.) This session examines how policy and pricing reforms across the U.S., Europe, and emerging markets are influencing one another. Experts will discuss global interdependencies—from IRA and MFN pricing to the EU JCA and Beneluxa—and share strategies for navigating evolving access frameworks and cross-regional impacts.
The GVD is Dead, Now What? Novel Approaches to Global/Local Collaboration for Access
Global & Regional Market Access (ex-U.S.) As traditional market access tools lose relevance, global teams are rethinking how to support affiliates effectively. This interactive workshop explores innovative collaboration models, smarter access tools, and emerging technologies that help local teams deliver stronger payer value propositions and drive efficient, country-specific access strategies.
The Price of Innovation: How Global Access Policies Are Reshaping Drug Development
Global & Regional Market Access (ex-U.S.) This panel examines how evolving pricing frameworks, reimbursement challenges, and policy reforms are influencing R&D priorities and investment decisions. Experts from pharma, biotech, and finance will discuss how these forces are reshaping innovation, commercialization strategies, and global patient access in an increasingly constrained market environment.
Health Technology Assessment of Biosimilars—Unlocking the Potential to Improve Patient Outcomes and Lower Costs Through Updated Treatment Pathways
U.S. Policy & Market Access This session explores how current HTA frameworks and treatment pathways may undervalue biosimilars’ potential to expand access and improve outcomes. Experts will examine international approaches, policy gaps, and practical strategies to optimize biosimilar adoption, align pricing with value, and ensure patients benefit from post-expiry innovation.
MFP Effectuation and 340B Rebate Model Learnings Multidisciplinary Panel
U.S Policy & Market Access This panel unites experts from manufacturers, pharmacies, and hospitals to discuss the intersection of MFP implementation and the evolving 340B Pilot Program. Panelists will examine regulatory, operational, and compliance challenges while sharing collaborative strategies to balance financial sustainability with improved patient access and community health.
These "Dis-United States:" Rethinking Market Access Strategies When State Policy Defines Access
U.S. Policy & Market Access As state-level policymaking increasingly shapes patient access, this session explores how market access teams can navigate a fragmented environment. Panelists will discuss emerging state trends, data-driven prioritization, and cross-functional strategies to align engagement, contracting, and patient-support programs with diverse and evolving state policy landscapes.
TrumpRx and Direct-to-Patient Sales
U.S. Policy & Market Access With the rise of Lilly Direct and the launch of TrumpRx, direct-to-patient commercial models are reshaping U.S. market access. This session examines emerging opportunities and challenges—from pricing and channel strategy to payer impact and brand control—as manufacturers evaluate whether, when, and how to engage in direct patient sales.
Pivot Points: Evolving Your Market Access Career for the Future
U.S. Policy & Market Access This session explores how market access professionals can expand their influence and leadership through strategic career moves. Senior leaders and executive search experts will discuss transitions across global, local, and commercial roles—highlighting opportunities, trade-offs, and how access expertise drives broader organizational impact and executive growth.